Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol

被引:197
作者
Berrendero, F [1 ]
Maldonado, R [1 ]
机构
[1] Univ Pompeu Fabra, Fac Ciencies Salut & Vida, Lab Neurofarmacol, Barcelona 08003, Spain
关键词
Delta(9)-tetrahydrocannabinol; CB1 cannabinoid receptor; opioid system; anxiety; light-dark box;
D O I
10.1007/s00213-002-1144-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Recent studies have shown that several pharmacological actions induced by cannabinoids, including antinociception and reward, involve the participation of the endogenous opioid system. Objectives: The present study was designed to examine the possible involvement of the different opioid receptors in the anxiolytic-like responses induced by Delta(9)-tetrahydrocannabinol (THC). Methods: The administration of a low dose of THC (0.3 mg/kg) produced clear anxiolytic-like responses in the light-dark box, as previously reported. The effects of the pretreatment with the CB1 cannabinoid receptor antagonist, SR 141716A (0.5 mg/kg), or the mu-opioid receptor antagonist, beta-funaltrexamine (5 mg/kg), the delta-opioid receptor antagonist, naltrindole (2.5 mg/kg) and the kappa-opioid receptor antagonist, nor-binaltorphimine (2.5 mg/kg) were evaluated on anxiolytic-like responses induced by THC. Results: SR 141716A completely blocked the anxiolytic-like response induced by THC, suggesting that this effect is mediated by CB1 cannabinoid receptors. The p-opioid receptor antagonist beta-funaltrexamine and the delta-opioid receptor antagonist naltrindole, but not the kappa-opioid receptor antagonist norbinaltorphimine, abolished THC anxiolytic-like effects, suggesting an involvement of mu- and delta-opioid receptors in this behavioural response. Conclusions: These results demonstrate that the endogenous opioid system is involved in the regulation of anxiety-like behaviour by cannabinoids and provide new findings to clarify further the interaction between these two neuronal systems.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 37 条
[1]   Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters [J].
Arévalo, C ;
de Miguel, R ;
Hernández-Tristán, R .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2001, 70 (01) :123-131
[2]   COMPARISON OF SOME PHARMACOLOGICAL ACTIONS OF MORPHINE AND DELTA-9-TETRAHYDROCANNABINOL IN MOUSE [J].
BLOOM, AS ;
DEWEY, WL .
PSYCHOPHARMACOLOGY, 1978, 57 (03) :243-248
[3]  
Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632
[4]   OPIOID AND CANNABINOID RECEPTOR INHIBITION OF ADENYLYL CYCLASE IN BRAIN [J].
CHILDERS, SR ;
FLEMING, L ;
KONKOY, C ;
MARCKEL, D ;
PACHECO, M ;
SEXTON, T ;
WARD, S .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1992, 654 :33-51
[5]   Delta-9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat [J].
Corchero, J ;
Avila, MA ;
Fuentes, JA ;
Manzanares, J .
LIFE SCIENCES, 1997, 61 (04) :PL39-PL43
[6]   Delta(9)-tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus [J].
Corchero, J ;
Fuentes, JA ;
Manzanares, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 323 (2-3) :193-195
[7]   Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal [J].
deFonseca, FR ;
Carrera, MRA ;
Navarro, M ;
Koob, GF ;
Weiss, F .
SCIENCE, 1997, 276 (5321) :2050-2054
[8]  
deFonseca FR, 1996, J PHARMACOL EXP THER, V276, P56
[9]  
DEVANE WA, 1988, MOL PHARMACOL, V34, P605
[10]  
DEWEY WL, 1986, PHARMACOL REV, V38, P151